Continuing Medical Education for Nurse Practitioners | Earn CME Credit

Credits2

Search

Page 7 of 7

Results 451 - 491 of 491

UIP, IPF, NSIP, CHP: Making Sense of the Letters

t2diabetes-slides2

Download Slides: Advancing T2DM Therapy with Confidence

t2diabetes-louise

Getting to Goal Can Be Difficult: Louise

t2diabetes-brian

Getting to Goal Can Be Difficult: Brian

A Personalized Approach to Managing Patients with Uncontrolled Asthma

Considering Biosimilars in Patients Failing their Initial Biologic

When to Switch? Biologically Experienced Patients with Spondyloarthritis

Innovator or Biosimilar for a Patient with Rheumatoid Arthritis

IL-gastro-case3

Ulcerative Colitis: What Can You Expect When a Patient is Switched to a Biosimilar?

IL-gastro-case2

Biosimilars in Patients with Crohn’s Disease Failing an Initial Biologic

IL-gastro-case1

Innovator or Biosimilar for a Patient with Ulcerative Colitis?

Switching Between Biologics: Is a Biosimilar an Option?

When to Switch? Biologically Experienced Psoriasis Patients

Innovator or Biosimilar for a Patient with Psoriasis

Interchangeability and Pharmacy-Level Substitution

FDA Criteria: Biosimilar Approval, Manufacturing, & Naming

What is the Difference Between a Biosimilar and a Generic?

What is a Biologic?

New Strides in EGFR Inhibition for Non–Small Cell Lung Cancer

Pete - Work-Up of a Patient with Right Upper Lobe Mass and Metastases

Carl - High Suspicion of Lung Cancer: Setting the Stage with a Good Biopsy

Are You Ready to Use Biosimilars in Your Practice?

Radiologic Features of IPF

Gwen: A lawyer with a history of MI has a dry cough and trouble with stairs

Elizabeth: Loves the outdoors but bothered by persistent cough and GERD

Toni: Too tired to continue teaching and experiencing painful heartburn

Individualizing Patient Education in Treatment Choice: Practical Strategies

Biosimilars in Clinical Practice: Interchangeability and Extrapolation

Individualizing Patient Education in Treatment Choice: Practical Strategies

Addressing Common Barriers to Adherence

Discovering New Drugs for IPF

Biomarkers for IPF

New Trends in IPF

New Trends in IPF

Treatment Dilemmas Case Study: Harrison

A New Era in IPF: Trials and Treatments

Highlights from ATS 2014: Discussions on Clinical Trial Data

Highlights from ATS 2014: Update on Predicting Clinical Progression

Highlights from ATS 2014: Top Line Clinical Trial Results - ASCEND, INPULSIS, and PANTHER

Exciting IPF Developments from 2015 ERS

Exciting Developments from 2015 CHEST

Page 7 of 7

The France Foundation

A ACCME Accredited provider.

The France Foundation ©

10 Vista Drive, Old Lyme, CT USA